ClinicalTrials.gg
RecruitingNCT07526675BioblationUpdated Sep 30, 2026

Concomitant Trans-Perineal Prostate Biopsy and Ablation (Bioblation) for Prostate Cancer

An interventional study of Bioblation in Prostate Cancer, Lower Urinary Tract Symptoms (LUTS) and Benign Prostatic Hyperplasia, sponsored by Benha University. Recruiting at 1 site in Egypt. Open to male participants aged 18 Months and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Benha University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Sep 30, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Months and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies in Prostatic Neoplasms with a site in Egypt — 7 open to participants now, 9 under way, none of them phase 3. Prostatic Neoplasms · Egypt.

Planned enrollment
17th of 18
30 · median 80
Started
2026
with 1 other
No phase
10 of 25
4 open now
Registered
23rd of 25
by date
Lead sponsor
1 of 25
Benha University

Among the 25 studies in Prostatic Neoplasms with a site in Egypt, this one is the 17th largest by planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2026, is one of 10 with no phase, and was the 23rd registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

7 of the 25 studies in Prostatic Neoplasms with a site in Egypt are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Months and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Prostatic Neoplasms with a site in Egypt, or all of them as a file.
02

Study summary

This prospective study aims to validate the clinical outcomes of performing a concomitant trans-perineal prostate biopsy and laser ablation (termed "Bioblation") during a single session. The intervention is designed for symptomatic patients presenting with lower urinary tract symptoms (LUTS) who are highly suspected to have low to favorable intermediate-risk prostate cancer. By combining diagnosis and targeted treatment under local anesthesia, this approach seeks to facilitate early relief of severe symptoms and a rapid return to daily activities. Ultimately, the study evaluates whether this combined procedure decreases the patient's exposure to multiple, temporally separated interventions without compromising oncological safety or efficacy.

03

Conditions studied

  • Prostate Cancer
  • Lower Urinary Tract Symptoms (LUTS)
  • Benign Prostatic Hyperplasia

Keywords

  • Prostate Cancer
  • Transperineal Laser Ablation
  • Bioblation
  • Focal Therapy
  • Lower Urinary Tract Symptoms
  • Benign Prostatic Hyperplasia
04

Who can participate

Ages eligible
18 Months and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with severe Lower Urinary Tract Symptoms (LUTS) meeting the following parameters:

    1. IPSS score > 20
    2. Uroflowmetry flow rate \< 10 ml/sec
    3. Post-void residual > 150 cc
  • Patients most probably having low to favorable intermediate-risk prostate cancer, defined as:

    1. PSA level between 4 and 20 ng/ml
    2. MP-MRI showing 3 or fewer focal lesions
    3. MP-MRI focal lesions measuring \< 1.5 cm
  • International or visiting patients requiring early return to their home country due to professional or personal commitments, provided they can undergo short-term management and follow-up coordination

Exclusion criteria

Exclusion Criteria:

  • Patient PSA level > 20 ng/ml
  • More than 3 focal lesions on MP-MRI
  • prostate cancer
  • History of lower urinary tract surgery (e.g., TURP, Laser, urinary diversions, artificial urinary sphincter)
  • History of pelvic radiation therapy or radical pelvic surgery
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Bioblation Group

    Patients with severe lower urinary tract symptoms (LUTS) and suspected low to favorable intermediate-risk prostate cancer undergoing concomitant trans-perineal prostate biopsy and laser ablation in a single session

    Procedure: Bioblation

Interventions

  • ProcedureBioblation

    The procedure is performed under local anesthesia and a prostatic nerve block. Under real-time transrectal ultrasound (TRUS) visualization, four biopsy cores are taken transperineally from each suspected focal lesion, alongside systematic biopsies of the transitional zones. Immediately following the biopsy, 18G Chipa needles are inserted transperineally to pass 300-micron laser fibers to the target site. Using the Elesta system, 7W of laser energy is delivered via MRI-guided cognitive fusion to induce thermal coagulative necrosis of the tumor.

    Also known as: Elesta laser system

06

What researchers measure

Primary outcomes

  1. Change in International Prostate Symptom Score (IPSS)

    The IPSS is a validated questionnaire used to assess the severity of lower urinary tract symptoms (LUTS). The total score ranges from 0 to 35, where 0-7 indicates mildly symptomatic, 8-19 moderately symptomatic, and 20-35 severely symptomatic. A decrease in the score indicates an improvement in symptoms.

    Time frame: Baseline, 1, 3, 6, 9, and 12 months post-procedure

Secondary outcomes

  1. Change in Maximum Urinary Flow Rate (Q-max)

    Maximum urinary flow rate will be measured using uroflowmetry to assess functional improvement in urination. It is measured in milliliters per second (mL/sec). A higher value indicates better urinary flow and less obstruction.

    Time frame: Baseline, 1, 3, 6, 9, and 12 months post-procedure

  2. Change in Post-Void Residual (PVR) Urine Volume

    PVR will be measured via ultrasound to determine the volume of urine remaining in the bladder immediately after urination. It is measured in milliliters (mL) or cubic centimeters (cc). A lower volume indicates better bladder emptying.

    Time frame: Baseline, 1, 3, 6, 9, and 12 months post-procedure

  3. Change in Prostate Volume

    Total prostate gland volume will be assessed using transrectal ultrasound (TRUS) or multiparametric MRI. It is measured in cubic centimeters (cc) or milliliters (mL). A decrease in volume indicates a reduction in gland size following the ablation procedure.

    Time frame: Baseline, 1, 3, 6, 9, and 12 months post-procedure

  4. Change in Total Serum Prostate-Specific Antigen (PSA)

    Measurement of total serum PSA levels (in ng/mL) to monitor oncological control, disease status, and therapeutic response following the focal ablation of the suspected prostate lesions.

    Time frame: Baseline, 1, 3, 6, 9, and 12 months post-procedure

  5. Incidence of Procedure-Related Complications

    The occurrence, type, and severity of post-operative adverse events (such as hematuria, acute urinary retention, fever, or signs of infection) will be recorded to evaluate the safety profile of the concomitant biopsy and ablation procedure.

    Time frame: Up to 12 months post-procedure

07

Study locations

1 of 1 sites recruiting
  • Urology Department, Benha University Hospitals
    Banhā, Qalyubia Governorate 13518, Egypt
    Recruiting
08

References and documents

Publications

  • McVary KT. (2016) BPH: Epidemiology and pathophysiology of benign prostatic hyperplasia. Urologic Clinics of North America. 43(3):289-297. Chapple CR, et al. (2008) Lower urinary tract symptoms revisited: A broader clinical perspective. European Urology. 54(3):563-569. Foster HE, Barry MJ, Dahm P, et al. (2021) Benign Prostatic Hyperplasia: AUA Guideline. J Urol. 206(4):806-817. McConnell JD, Roehrborn CG. (2021) Benign Prostatic Hyperplasia: Diagnosis and Treatment. In: Wein AJ, Kavoussi LR, Partin AW, Peters CA, editors. Campbell-Walsh-Wein Urology, 12th ed. Elsevier. Siegel RL, Miller KD, Fuchs HE, Jemal A. (2024) Cancer Statistics. CA Cancer J Clin. 2024;74:7-33. Culp SH, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. (2020) Recent Global Patterns in Prostate Cancer Incidence and Mortality Among Younger Men. Eur Urol. 77(2):125-133. Mohler JL, et al. (2025) Prostate Cancer, NCCN Guidelines Version 2.2025. J Natl Compr Canc Netw. 23:114-159. Kasivisvanathan V, et al. (2018) MRI-targeted vs Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 378:1767-1777. Pacella CM, Breschi L, Bottacci D, Masotti L. (2020) Physical principles of laser ablation. In: Pacella C, Jiang T, Mauri G, editors. Image-guided laser ablation. Cham, Switzerland: Springer. Amzayyb M, van den Bos RR, Kodach VM, et al. (2010) Carbonized blood deposited on fibres during 810, 940 and 1,470 nm endovenous laser ablation: thickness and absorption by optical coherence tomography. Lasers Med Sci:25:439-47. van Riel LA, van Kollenburg RAA, Vis AN, van Leeuwen PJ, de Reijke TM, de Bruin DM et al. (2022) Safety and Feasibility of Soractelite Transperineal Focal Laser Ablation for Prostate Cancer and Short-term Quality of Life Analysis from a Multicenter Pilot Study. Eur Urol Open Sci:39:48-54. Frego N, Saita A, Casale P, Diana P, Contieri R, et al. (2021) Feasibility, safety, and efficacy of ultrasound-guided transperineal laser ablation for the treatment of benign prostatic hyperpl

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Apr 2027, 12 months after the start.

Of 1,100 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 12 months is below that.

Counting every sponsor, half of 1,157 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Apr 2026 → Apr 2027 and completion Apr 2026 → Apr 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2026
First posted
Apr 13, 2026
StartActual
Apr 10, 2026
Primary completionEst.
Apr 20, 2027was Apr 2026
CompletionEst.
Apr 28, 2027was Apr 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 30, 2026
Sites
Urology Department, Benha University Hospitals is now Recruiting
Sep 30, 2026
Primary completion
Apr 20, 2026→Apr 20, 2027
Sep 30, 2026
Study completion
Apr 28, 2026→Apr 28, 2027
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Not yet recruiting→Recruiting
    Urology Department, Benha University Hospitals is now Recruiting
    Primary completion Apr 20, 2026→Apr 20, 2027
    Study completion Apr 28, 2026→Apr 28, 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07526675
Lead sponsor
Benha University
Responsible party
Ahmed Al-Lithi (Dr, Benha University) — Principal investigator
First posted
Apr 13, 2026
Start date
Apr 10, 2026
Primary completion
Apr 20, 2027 (estimated)
Completion
Apr 28, 2027 (estimated)
Last update
Sep 30, 2026

Study contacts

Ahmed Mohamed AL-Lithi, MBBCh Medical Degree
Contact
ahmedallithi@gmail.com
+201007128247

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion